Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 24;64(1):151-160.
doi: 10.2478/jvetres-2020-0018. eCollection 2020 Mar.

Cyclooxygenase-2 as a Biomarker with Diagnostic, Therapeutic, Prognostic, and Predictive Relevance in Small Animal Oncology

Marta Szweda  1 , Andrzej Rychlik  2 , Izabella Babińska  3 , Andrzej Pomianowski  1
Affiliations

Cyclooxygenase-2 as a Biomarker with Diagnostic, Therapeutic, Prognostic, and Predictive Relevance in Small Animal Oncology

Marta Szweda et al. J Vet Res. .

Abstract

In canine and feline populations, the number of neoplasm cases continues to increase around the world. Attempts are being made in centres of research to identify new biomarkers that speed up and improve the quality of oncological diagnostics and therapy in human and animal tumour patients. Cyclooxygenase-2 (COX-2) is a promising biomarker with increasing relevance to human oncology, but as yet with less application in veterinary oncology. The expression of COX-2 increases significantly during pathological processes involving inflammation, pain or fever. It is also overexpressed in humans presenting various types of tumours and in selected types of tumours in animals, particularly in dogs. This article discusses the expression of COX-2 in canine and feline tumours, the importance of COX-2 as a biomarker with diagnostic, therapeutic, prognostic and predictive relevance in oncology, and the clinical significance of inhibiting COX-2 overexpression in tumours.

Keywords: COX-2; biomarker; cat; dog; tumours.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Conflict of Interests Statement: The authors declare that there is no conflict of interests regarding the publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anadol E., Yar Saglam A.S., Gultiken N., Karakas K., Alcigir E., Alkan H., Kanca H.. Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopathological features and tumour grade. Acta Vet Hung. 2017;65:382–393. - PubMed
    1. Araújo M.R., Campos L.C., Damasceno K.A., Gamba C.O., Ferreira E., Cassali G.D.. HER-2, EGFR, Cox-2, and Ki67 expression in lymph node metastasis of canine mammary carcinomas: association with clinical-pathological parameters and overall survival. Res Vet Sci. 2016;106:121–130. - PubMed
    1. Arber N., Eagle C.J., Spicak J., Rácz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B.. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895. - PubMed
    1. Arenas C., Peña L., Granados-Soler J.L., Pérez-Alenza M.D.. Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study. Vet Rec. 2016;179:125. - PubMed
    1. Badowska-Kozakiewicz A.M.. Biological role of cyclooxygenase-2 in veterinary oncology. Życie Wet. 2011;86:862–864.

LinkOut - more resources